Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib drug-drug interaction study with anastrozole, letrozole, and tamoxifen in advanced solid tumors
NL-OMON40826Phase 1Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Oct 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of olaparib, tamoxifen, anastrozole and letrozole in Nonhematologic neoplasms (3 cohorts), sponsored by AstraZeneca. Primary endpoints: Steady-state maximum plasma concentration, Steady-state area under the plasma concentration-time curve over the dosing interval and 1 more. Started Oct 2014; status: active, not recruiting.
02
Drugs
olaparibtamoxifenanastrozoleletrozole
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON40826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40826.